BMT CTN
@BMTCTN
Followers
4K
Following
197
Media
92
Statuses
845
Blood and Marrow Transplant Clinical Trials Network
Joined October 2014
This will be happy news for patients!
#ASH24 Thanks @Medscape for featuring our @BMTCTN analysis around 24-hour urine testing in #MMsm. Not time to stop for everyone, but its role in myeloma (outside of AL amyloidosis) will be heavily de-emphasized soon! https://t.co/f33Xkuzo5Q
0
1
4
A new risk assessment model developed by investigators from @BMTCTN to assess transplant success in older patients will be presented by Fred Hutch's @msorror at #ASH24.
fredhutch.org
A new risk assessment model developed by investigators from the Blood & Marrow Transplant Clinical Trials Network (BMT CTN) will be presented by Fred Hutch Cancer Center transplant doctor Mohamed...
0
2
6
New research at #ASH24 by @BMTCTN, presented by @StephanieLeeMD @fredhutch shows using a donor prognosis score accelerates HCT for patients by prioritizing alternative donors when a full match is unlikely, maintaining similar clinical outcomes https://t.co/EPTdKqsrkY
0
2
8
A new @BMTCTN study shows that giving gilteritinib after BMT helps people who have FLT3 AML and have MRD. Read more about this study: https://t.co/eGyqfoNUJP
0
2
2
A new @BMTCTN study shows that despite side effects, people who got #BMT for treating MDS had similar quality of life to people who didn’t get BMT. And people who got BMT were more likely to survive 3 years after treatment. https://t.co/d80hunzBgH
0
2
1
Congratulations to #BMTCTN 1703 team, investigators and their teams, and most importantly, the patients who participated. A communal effort that yielded incredible results! @GvHD_Meade @sghmd @MediHumdani
An incredible amount of work with really brilliant people made #BMTCTN1703 a success and the new SOC for #GvHD prophylaxis #PTCyRules #BMTCTN @CIBMTR Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis | NEJM
0
13
31
It's official! #BMTCTN 1703 (PROGRESS III; Acute GVHD Prophy PTCy vs. Tac/Mtx) selected as Late-Breaking Abstract at #ASH22! Congrats to the protocol team and participating sites; and special thanks the patients who participated. https://t.co/50JS7Xi3Nx
⏰ #ASH22 LATE BREAKING ABSTRACT ANNOUNCEMENT! ⏰ It's a big year for post-transplant cyclophosphamide (PTCy) and @BMTCTN! The primary analysis of #BMTCTN1703 is here! https://t.co/8M6yACHe7m A thread 🧵/ @ASHClinicalNews @ASH_hematology
0
3
14
Excited to have @sumithira_vasu lead this new committee--so much important work to be done!
Congrats, @sumithira_vasu for being invited to serve as Chair of the @BMTCTN Patient and Caregiver Advocacy Committee. She will review all protocols that will be developed at the BMT CTN to advocate for patients and caregivers. 👩⚕️ @OSUCCC_James @OSUWexMed #patientexpereince
0
1
7
Nominations now being accepted for the new #BMTCTN Patient and Caregiver Advocacy Committee! For more information: https://t.co/OT6fwoCDLU
1
3
4
Recommend Dr. Wingard's Perspectives article providing historical context of the #BMTCTN--he has a great vantagepoint as the Network's first Steering Committee Chair!
The CIBMTR August Newsletter is now available online. Read updates about Working Committees (Immunobiology; Graft Sources and Manipulation), BMT CTN COVID Vaccination study, new BMT CTN website and logo, HLA typing practices, PRO, and more! Read here: https://t.co/Uks0eX0b5C
0
1
6
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502) #BMTsm @AmyDeZern @BMTCTN @aamdsif #PTCy
0
5
18
Doctors should team up to diagnose acute graft-versus-host disease, or AGVHD, more accurately. That’s according to new research from the @BMTCTN. Read more: https://t.co/NExbI5ftSy
1
2
3